Intrabodies for protein interference in Alzheimers disease

G Meli, N Krako, A Manca, A Lecci, A Cattaneo

Article ID: 6728
Vol 27, Issue 2S1, 2013
DOI: https://doi.org/10.54517/jbrha6728
Received: 9 July 2013; Accepted: 9 July 2013; Available online: 9 July 2013; Issue release: 9 July 2013

Abstract

Several open questions call for new studies on pathogenic mechanisms leading to Alzheimers Disease (AD), with the search for upstream drivers of the neurodegeneration cascade, such as neurotrophic deficits, early misfolding events of AD-related proteins (Abeta and tau) and understanding the multifactorial basis of AD pathogenesis. Since seminal immunosympathectomy experiment which represents the first example of a knock out experiment (albeit a protein knock-out), antibodies have had a long and successful history as a tool to selectively interfere with the function of proteins in cells and in organisms and antibody technologies represent a major weapon in the set of target validation techniques. Here, we describe a technology, pioneered by our group, based on recombinant antibody domains exploited as intracellular antibodies (intrabodies) whereby antibodies are used as genes, rather than as proteins. We discuss several applications and new promising developments of the intrabody approach for protein interference, especially in the field of AD research.


Keywords

Intrabodies;Alzheimers Disease;protein interference;Amyloid-beta;tau


References

Supporting Agencies



Copyright (c) 2013 G Meli, N Krako, A Manca, A Lecci, A Cattaneo




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).